Patents by Inventor Qiren LIANG
Qiren LIANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11905297Abstract: Methods and compositions for agonizing a type-2 orexin receptor (OX2R) in a cell determined to be in need thereof, including the general method of (a) administering to a subject a cyclic guanidinyl OX2R agonist and (b) detecting a resultant enhanced wakefulness or increased resistance to diet-induced accumulation of body fat, or abbreviated recovery from general anesthesia or jet lag.Type: GrantFiled: October 21, 2022Date of Patent: February 20, 2024Assignee: Board of Regents, The University of Texas SystemInventors: Jef De Brabander, Daniel Rosenbaum, Qiren Liang, Wentian Wang
-
Publication number: 20230203020Abstract: Small molecule disruptors of Beclin-1/Bcl-2 protein-protein interactions induce autophagy and hence are useful for treating a variety of indications where stimulation of autophagy is therapeutically useful, including cancer, infection immunity, neurodegeneration, longevity.Type: ApplicationFiled: February 11, 2023Publication date: June 29, 2023Applicant: Board of Regents, The University of Texas SystemInventors: Jef De Brabander, Qiren Liang, Beth Levine, Wei-Chung Chiang
-
Publication number: 20230122024Abstract: Methods and compositions for agonizing a type-2 orexin receptor (OX2R) in a cell determined to be in need thereof, including the general method of (a) administering to a subject a cyclic guanidinyl OX2R agonist and (b) detecting a resultant enhanced wakefulness or increased resistance to diet-induced accumulation of body fat, or abbreviated recovery from general anesthesia or jet lag.Type: ApplicationFiled: October 21, 2022Publication date: April 20, 2023Applicant: Board of Regents, The University of Texas SystemInventors: Jef De Brabander, Daniel Rosenbaum, Qiren Liang, Wentian Wang
-
Patent number: 11591319Abstract: Small molecule disruptors of Beclin-1/Bc1-2 protein-protein interactions induce autophagy and hence are useful for treating a variety of indications where stimulation of autophagy is therapeutically useful, including cancer, infection immunity, neurodegeneration, longevity.Type: GrantFiled: April 5, 2022Date of Patent: February 28, 2023Assignee: Board of Regents, The University of Texas SystemInventors: Jef De Brabander, Qiren Liang, Beth Levine, Wei-Chung Chiang
-
Patent number: 11479560Abstract: Methods and compositions for agonizing a type-2 orexin receptor (OX2R) in a cell determined to be in need thereof, including the general method of (a) administering to a subject a cyclic guanidinyl OX2R agonist and (b) detecting a resultant enhanced wakefulness or increased resistance to diet-induced accumulation of body fat, or abbreviated recovery from general anesthesia or jet lag.Type: GrantFiled: November 20, 2020Date of Patent: October 25, 2022Inventors: Jef De Brabander, Daniel Rosenbaum, Qiren Liang, Wentian Wang
-
Patent number: 11472813Abstract: Methods and compositions for agonizing a type-2 orexin receptor (OX2R) in a cell determined to be in need thereof, including the general method of (a) administering to a subject a cyclic guanidinyl OX2R agonist and (b) detecting a resultant enhanced wakefulness or increased resistance to diet-induced accumulation of body fat, or abbreviated recovery from general anesthesia or jet lag.Type: GrantFiled: September 27, 2020Date of Patent: October 18, 2022Assignee: Board of Regents, The University of Texas SystemInventors: Jef De Brabander, Daniel Rosenbaum, Qiren Liang, Wentian Wang
-
Publication number: 20220242854Abstract: Small molecule disruptors of Beclin-1/Bc1-2 protein-protein interactions induce autophagy and hence are useful for treating a variety of indications where stimulation of autophagy is therapeutically useful, including cancer, infection immunity, neurodegeneration, longevity.Type: ApplicationFiled: April 5, 2022Publication date: August 4, 2022Applicant: Board of Regents, The University of Texas SystemInventors: Jef De Brabander, Qiren Liang, Beth Levine, Wei-Chung Chiang
-
Patent number: 11325898Abstract: Small molecule disruptors of Beclin-1/Bcl-2 protein-protein interactions induce autophagy and hence are useful for treating a variety of indications where stimulation of autophagy is therapeutically useful, including cancer, infection immunity, neurodegeneration, longevity.Type: GrantFiled: December 4, 2020Date of Patent: May 10, 2022Assignee: Board of Regents, The University of Texas SystemInventors: Jef De Brabander, Qiren Liang, Beth Levine, Wei-Chung Chiang
-
Publication number: 20210163494Abstract: Methods and compositions for agonizing a type-2 orexin receptor (OX2R) in a cell determined to be in need thereof, including the general method of (a) administering to a subject a cyclic guanidinyl OX2R agonist and (b) detecting a resultant enhanced wakefulness or increased resistance to diet-induced accumulation of body fat, or abbreviated recovery from general anesthesia or jet lag.Type: ApplicationFiled: November 20, 2020Publication date: June 3, 2021Applicant: Board of Regents, The University of Texas SystemInventors: Jef De Brabander, Daniel Rosenbaum, Qiren Liang, Wentian Wang
-
Publication number: 20210115024Abstract: Small molecule disruptors of Beclin-1/Bcl-2 protein-protein interactions induce autophagy and hence are useful for treating a variety of indications where stimulation of autophagy is therapeutically useful, including cancer, infection immunity, neurodegeneration, longevity.Type: ApplicationFiled: December 4, 2020Publication date: April 22, 2021Applicant: Board of Regents, The University of Texas SystemInventors: Jef De Brabander, Qiren Liang, Beth Levine, Wei-Chung Chiang
-
Publication number: 20210107914Abstract: Methods and compositions for agonizing a type-2 orexin receptor (OX2R) in a cell determined to be in need thereof, including the general method of (a) administering to a subject a cyclic guanidinyl OX2R agonist and (b) detecting a resultant enhanced wakefulness or increased resistance to diet-induced accumulation of body fat, or abbreviated recovery from general anesthesia or jet lag.Type: ApplicationFiled: September 27, 2020Publication date: April 15, 2021Applicant: Board of Regents, The University of Texas SystemInventors: Jef De Brabander, Daniel Rosenbaum, Qiren Liang, Wentian Wang
-
Publication number: 20180354909Abstract: Provided herein are compounds of the formula:(I) wherein: R1, R2, R3, R4, R5, X, A1, A2, A3, and A4 are as defined herein. In some aspects, these compounds may be used to treat cancer and other hyperproliferative disease. In some aspects, compositions, methods of treatment, and methods of synthesis are also provided herein.Type: ApplicationFiled: December 9, 2016Publication date: December 13, 2018Applicant: The Board of Regents of the University of Texas SystemInventors: Jef DE BRABANDER, Luis F. PARADA, S. Kyun LIM, Qiren LIANG, Hua-yu WANG, Yufeng SHI